Cable Hill Partners, LLC - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 158 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.

Quarter-by-quarter ownership
Cable Hill Partners, LLC ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2019$22,000
+10.0%
4,7290.0%0.01%
-12.5%
Q4 2018$20,000
-23.1%
4,729
+10.5%
0.01%
-27.3%
Q3 2018$26,000
-25.7%
4,279
-1.2%
0.01%
-26.7%
Q2 2018$35,000
+12.9%
4,3290.0%0.02%
+15.4%
Q1 2018$31,000
+72.2%
4,329
+50.4%
0.01%
+62.5%
Q4 2017$18,000
-14.3%
2,878
+0.9%
0.01%
-20.0%
Q3 2017$21,000
+250.0%
2,852
+226.7%
0.01%
+233.3%
Q2 2017$6,000
-25.0%
873
-0.3%
0.00%
-25.0%
Q1 2017$8,0000.0%876
-4.6%
0.00%0.0%
Q4 2016$8,0009180.00%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q2 2018
NameSharesValueWeighting ↓
Broadfin Capital, LLC 17,902,338$135,342,0005.88%
TIGER MANAGEMENT L.L.C. 1,288,454$9,741,0001.91%
Phocas Financial Corp. 1,047,181$7,917,0000.69%
TUDOR INVESTMENT CORP ET AL 2,370,503$17,921,0000.62%
EAM Investors, LLC 553,309$4,183,0000.58%
Baker Brothers Advisors 4,449,797$33,640,0000.34%
TFS CAPITAL LLC 463,740$3,506,0000.33%
FEDERATED HERMES, INC. 13,508,290$102,123,0000.32%
Rotella Capital Management, Inc. 36,473$276,0000.24%
OXFORD ASSET MANAGEMENT LLP 1,103,848$8,351,0000.18%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders